Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis

Objectives: To quantify the duration of each step of the diagnostic pathway for patients with multiple myeloma from symptom onset to confirmation of diagnosis. Design: Systematic review and meta-analysis. Data sources and selection criteria: The MEDLINE and Embase databases were searched up until...

Full description

Bibliographic Details
Main Authors: Koshiaris, CK, Oke, J, Abel, L, Nicholson, BD, Ramasamy, Van den Bruel, AVD
Format: Journal article
Published: BMJ Publishing Group 2018
_version_ 1797091209679732736
author Koshiaris, CK
Oke, J
Abel, L
Nicholson, BD
Ramasamy,
Van den Bruel, AVD
author_facet Koshiaris, CK
Oke, J
Abel, L
Nicholson, BD
Ramasamy,
Van den Bruel, AVD
author_sort Koshiaris, CK
collection OXFORD
description Objectives: To quantify the duration of each step of the diagnostic pathway for patients with multiple myeloma from symptom onset to confirmation of diagnosis. Design: Systematic review and meta-analysis. Data sources and selection criteria: The MEDLINE and Embase databases were searched up until January 2018 to identify articles that reported time intervals from onset of symptoms to diagnosis. Articles focusing on children or adolescents and on the asymptomatic form of the disease (monoclonal gammopathies and smouldering myeloma) were excluded. Data collection and data analysis: Data were extracted independently by two reviewers. Weighted estimates of the median and IQR were calculated. Risk of bias was assessed using the Aarhus checklist. Main results: Nine studies were included. The patient interval (first symptom to first presentation) had a median of 26.3 days (IQR: 1–98, n=465, two studies). Subsequently, the primary care interval (first presentation to first referral) was 21.6 days (IQR: 4.6–55.8, n=326, two studies), the diagnostic interval (first presentation to diagnosis) was 108.6 days (IQR: 33.3–241.7, n=5395, seven studies) and the time to diagnosis (first symptom to diagnosis) interval was 163 days (IQR: 84–306, n=341, one study). No studies reported data for the referral to diagnosis interval. Conclusion: The review demonstrates that there is scope for significant reductions in the time to myeloma diagnosis. At present, many patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed.
first_indexed 2024-03-07T03:29:43Z
format Journal article
id oxford-uuid:ba4923da-f36f-4630-9835-7975ade25b6f
institution University of Oxford
last_indexed 2024-03-07T03:29:43Z
publishDate 2018
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:ba4923da-f36f-4630-9835-7975ade25b6f2022-03-27T05:08:46ZQuantifying intervals to diagnosis in myeloma: a systematic review and meta-analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ba4923da-f36f-4630-9835-7975ade25b6fSymplectic Elements at OxfordBMJ Publishing Group2018Koshiaris, CKOke, JAbel, LNicholson, BDRamasamy,Van den Bruel, AVDObjectives: To quantify the duration of each step of the diagnostic pathway for patients with multiple myeloma from symptom onset to confirmation of diagnosis. Design: Systematic review and meta-analysis. Data sources and selection criteria: The MEDLINE and Embase databases were searched up until January 2018 to identify articles that reported time intervals from onset of symptoms to diagnosis. Articles focusing on children or adolescents and on the asymptomatic form of the disease (monoclonal gammopathies and smouldering myeloma) were excluded. Data collection and data analysis: Data were extracted independently by two reviewers. Weighted estimates of the median and IQR were calculated. Risk of bias was assessed using the Aarhus checklist. Main results: Nine studies were included. The patient interval (first symptom to first presentation) had a median of 26.3 days (IQR: 1–98, n=465, two studies). Subsequently, the primary care interval (first presentation to first referral) was 21.6 days (IQR: 4.6–55.8, n=326, two studies), the diagnostic interval (first presentation to diagnosis) was 108.6 days (IQR: 33.3–241.7, n=5395, seven studies) and the time to diagnosis (first symptom to diagnosis) interval was 163 days (IQR: 84–306, n=341, one study). No studies reported data for the referral to diagnosis interval. Conclusion: The review demonstrates that there is scope for significant reductions in the time to myeloma diagnosis. At present, many patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed.
spellingShingle Koshiaris, CK
Oke, J
Abel, L
Nicholson, BD
Ramasamy,
Van den Bruel, AVD
Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title_full Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title_fullStr Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title_full_unstemmed Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title_short Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
title_sort quantifying intervals to diagnosis in myeloma a systematic review and meta analysis
work_keys_str_mv AT koshiarisck quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis
AT okej quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis
AT abell quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis
AT nicholsonbd quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis
AT ramasamy quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis
AT vandenbruelavd quantifyingintervalstodiagnosisinmyelomaasystematicreviewandmetaanalysis